The University of Chicago Header Logo

Connection

Mary Eileen Dolan to Bevacizumab

Back to Details
This is a "connection" page, showing publications Mary Eileen Dolan has written about Bevacizumab.
Mary Eileen Dolan
Connection Strength
0.030
Bevacizumab
  1. Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res. 2016 Oct 01; 22(19):4890-4900.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.